

=>

Uploading 050.str

L1        STRUCTURE UPLOADED

=> s l1 sss ful

FULL SEARCH INITIATED 17:16:55 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -    2251 TO ITERATE

100.0% PROCESSED        2251 ITERATIONS

47 ANSWERS

SEARCH TIME: 00.00.01


L2                47 SEA SSS FUL L1

=> d scan

L2    47 ANSWERS    REGISTRY    COPYRIGHT 2003 ACS on STN

IN    Propanoic acid, 3-[[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-methylphenyl]amino]-3-oxo- (9CI)

MF    C19 H19 Cl2 N O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):n

=> d his

(FILE 'HOME' ENTERED AT 17:15:41 ON 11 DEC 2003)

FILE 'REGISTRY' ENTERED AT 17:15:59 ON 11 DEC 2003

L1 STRUCTURE UPLOADED  
L2 47 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 17:17:05 ON 11 DEC 2003

=> s 12

L3 6 L2

=> d bib, hit 1-

YOU HAVE REQUESTED DATA FROM 6 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 2003:376560 CAPLUS  
DN 138:385172  
TI Process for the preparation of aniline-derived thyroid receptor ligands  
with improved safety and economy  
IN Chidambaram, Ramakrishnan; Kant, Joydeep; Weaver, Raymond E., Jr.; Yu,  
Jurong; Ghosh, Arun  
PA Bristol-Myers Squibb Company, USA  
SO PCT Int. Appl., 70 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003039456	A2	20030515	WO 2002-US34592	20021028
	WO 2003039456	A3	20031002		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003157671	A1	20030821	US 2002-273268	20021017
PRAI	US 2001-336318P	P	20011102		
OS	MARPAT 138:385172				
IT	<b>355129-15-6P</b> , N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl]malonamic acid <b>355129-16-7P</b> , N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenyl]malonamic acid <b>355129-17-8P</b> , N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)-2-methylphenyl]malonamic acid <b>355129-18-9P</b> , N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl]succinamic acid <b>525584-74-1P</b> , N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)-2-methylphenyl]malonamic acid <b>525584-75-2P</b> , N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenyl]succinamic acid RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation) (process for prepn. of aniline-derived thyroid receptor ligands with improved safety and economy)				

L3 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2002:905927 CAPLUS  
 DN 138:305  
 TI Preventive or recurrence-suppressive agents for liver cancer  
 IN Ohnota, Hideki; Hayashi, Morimichi; Kuroda, Junji; Komatsu, Yoshimitsu;  
 Nishimura, Toshihiro  
 PA Kissei Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 142 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002094319	A1	20021128	WO 2002-JP4601	20020513
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI JP 2001-149775 A 20010518

OS MARPAT 138:305

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT	355129-15-6P	355129-23-6P	364331-19-1P	364331-20-4P	
	364331-24-8P	364332-53-6P	364332-59-2P	364332-60-5P	373641-10-2P
	373641-11-3P	373641-12-4P	373641-13-5P	373641-14-6P	373641-15-7P
	373641-16-8P	373641-17-9P	373641-18-0P	373641-19-1P	373641-20-4P
	373641-22-6P	373641-24-8P	373641-25-9P	373641-27-1P	373641-29-3P
	373641-31-7P	373641-34-0P	373641-36-2P	373641-38-4P	
	373641-40-8P	373641-42-0P	373641-44-2P	373641-46-4P	
	373641-48-6P	373641-49-7P	373641-50-0P	373641-51-1P	373641-53-3P
	373641-54-4P	373641-56-6P	373641-57-7P	373641-58-8P	373641-59-9P
	373641-60-2P	373641-61-3P	373641-62-4P	373641-63-5P	
	373641-64-6P	373641-65-7P	373641-66-8P	373641-67-9P	373641-68-0P
	373641-69-1P	373641-70-4P	373641-71-5P	373641-72-6P	373641-73-7P
	373641-74-8P	373641-75-9P	373641-76-0P	373641-77-1P	373641-78-2P
	373641-79-3P	373641-80-6P	373641-81-7P	373641-82-8P	373641-83-9P
	373641-84-0P	373641-85-1P	373641-86-2P	373641-87-3P	373641-88-4P
	373641-89-5P	373641-90-8P	373641-91-9P	373641-92-0P	477274-10-5P
	477274-11-6P	477274-12-7P			

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN  
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);  
 PREP (Preparation); USES (Uses)

(preventive or recurrence-suppressive agents for liver cancer contg.  
 thyroid hormone receptor agonists)

IT 2423-71-4P, 2,6-Dimethyl-4-nitrophenol 3886-19-9P, 2,6-  
 Dibenzoyloxyacetophenone 4049-39-2P, 4-Benzyloxy-3-hydroxybenzaldehyde  
 20404-02-8P, 2,3,6-Trichloro-4-nitrophenol 23860-35-7P,  
 Cyclohexylacetylchloride 29417-96-7P 40500-05-8P 53906-85-7P,  
 4-Iodo-3,5-dimethylnitrobenzene 85064-61-5P, 4-Tetrahydropyranylacetic  
 acid 92892-06-3P 103260-44-2P 117832-15-2P 130312-00-4P  
 156740-97-5P, 4-(4-Methoxyphenoxy)-3,5-dimethylnitrobenzene  
 355377-72-9P, 5-(2,6-Dimethyl-4-nitrophenoxy)-2-methoxybenzaldehyde  
 373641-93-1P 373641-94-2P 373641-96-4P 373641-97-5P,  
 4-Benzyloxy-3-(4-fluorophenoxy)benzaldehyde 373641-98-6P 373641-99-7P

373642-00-3P 373642-01-4P 373642-02-5P 373642-03-6P,  
 4-Benzyloxy-3-isopropylbenzaldehyde 373642-05-8P 373642-07-0P  
 373642-09-2P 373642-10-5P 373642-12-7P 373642-14-9P 373642-16-1P  
 373642-18-3P 373642-20-7P, 1-Benzyloxy-4-(2,3,6-trichloro-4-  
 nitrophenoxy)-5,6,7,8-tetrahydronaphthalene 373642-22-9P,  
 3-Chloro-6-[5-(2,6-dimethyl-4-nitrophenoxy)-2-methoxybenzyl]pyridazine  
 373642-24-1P, 1-[6-Benzyloxy-3-(2,6-dimethyl-4-nitrophenoxy)-2-  
 hydroxyphenyl]ethanone 373642-26-3P, 1-[6-Benzyloxy-3-(2,6-dimethyl-4-  
 nitrophenoxy)-2-methoxyphenyl]ethanone 373642-28-5P 373642-30-9P  
 373642-32-1P, N,N-Dibenzyl-4-iodo-3,5-dimethylaniline 373642-34-3P,  
 (4-Benzyloxy-3-isopropylphenyl)(4-dibenzylamino-2,6-  
 dimethylphenyl)methanol 373642-37-6P 373642-39-8P,  
 [4-Benzyloxy-3-(4-fluorophenoxy)phenyl](4-dibenzylamino-2,6-  
 dimethylphenyl)methanol 373642-41-2P 373642-43-4P 373642-45-6P  
 373642-47-8P 373642-49-0P 373642-51-4P 373642-53-6P,  
 5-(2,6-Dimethyl-4-nitrophenoxy)-2-hydroxybenzaldehyde 373642-55-8P  
 373642-61-6P 373642-62-7P 373642-63-8P 373642-66-1P 373642-67-2P  
 373642-68-3P 373642-69-4P 373642-70-7P 373642-71-8P 373642-72-9P  
 373642-73-0P 373642-75-2P 373642-76-3P 373642-77-4P 373642-78-5P  
 373642-79-6P 373642-80-9P, 3-[3-[5-(4-Amino-2,6-dimethylphenoxy)-2-  
 hydroxybenzyl]phenyl]propanoic acid 373642-82-1P 373642-83-2P,  
 1-[5-(4-Amino-2,6-dimethylphenoxy)-2-hydroxyphenyl]-2-cyclohexylethanone  
 373642-84-3P, 4-(4-Amino-2,6-dimethylphenoxy)-2-(2-cyclohexylethyl)phenol  
 373642-85-4P, 4-(4-Amino-2,6-dimethylphenoxy)-2-isopropyl-3-methoxyphenol  
 373642-86-5P, 4-[4-Methoxy-3-[2-(2-methoxyphenyl)ethyl]phenoxy]-3,5-  
 dimethylaniline 373642-87-6P, (4-Amino-2,6-dimethylphenyl)(4-hydroxy-3-  
 isopropylphenyl)methanone 373642-88-7P, 4-(4-Amino-2,6-dimethylbenzyl)-2-  
 isopropylphenol 373642-89-8P, 4-(4-Methoxybenzyl)-3,5-dimethylaniline  
 373642-91-2P, 4-(4-Amino-2,6-dimethylphenoxy)-2-(4-  
 tetrahydropyranyloxy)phenol 373642-92-3P, 4-(4-Amino-2,6-dimethylbenzyl)-  
 2-(4-tetrahydropyranyloxy)phenol 373642-93-4P, 1-(4-Amino-2,6-  
 dimethylphenoxy)-4-benzyloxy-5,6,7,8-tetrahydronaphthalene 373642-94-5P,  
 4-(4-Benzyloxy-3-isopropylphenoxy)-2,3,5-trichloroaniline 373642-95-6P,  
 4-(4-Benzyloxy-3-isopropylphenoxy)-3,5-dibromoaniline 373642-96-7P  
 373642-97-8P, 4-(4-Benzyloxy-5,6,7,8-tetrahydro-1-naphthyloxy)-2,3,5-  
 trichloroaniline 373642-98-9P, 6-[5-(4-Amino-2,6-dimethylphenoxy)-2-  
 hydroxybenzyl]-2H-pyridazin-3-one 373643-00-6P 373643-01-7P  
 373643-02-8P 373643-03-9P 373643-04-0P 373643-05-1P,  
 2,2,2-Trifluoro-N-[4-(4-methoxybenzyl)-3,5-dimethylphenyl]acetamide  
 373643-06-2P, 2,2,2-Trifluoro-N-[4-[3-(4-fluorobenzoyl)-4-hydroxybenzyl]-  
 3,5-dimethylphenyl]acetamide 373643-07-3P 373643-08-4P,  
 4-(4-Amino-2,6-dimethylphenoxy)-2-(2-cyclohexyl-1-hydroxyethyl)phenol  
 373643-09-5P, [5-(4-Amino-2,6-dimethylphenoxy)-2-hydroxyphenyl](2-  
 methoxyphenyl)methanone 373643-10-8P, [5-(4-Amino-2,6-dimethylphenoxy)-2-  
 hydroxyphenyl](2-hydroxyphenyl)methanone 373643-11-9P 373643-12-0P,  
 4-(4-Amino-2,6-dimethylbenzyl)-2-(4-fluorophenoxy)phenol 373643-15-3P  
 373643-16-4P 373643-17-5P 373643-18-6P 373643-19-7P 373643-20-0P  
**373643-21-1P** 373643-23-3P 477274-13-8P 477274-14-9P,  
 [2-Benzyloxy-5-(2,6-dimethyl-4-nitrophenyl)phenyl]methanol 477274-15-0P,  
 [5-(2,6-Dimethyl-4-nitrophenyl)-2-methoxyphenyl]methanol 477274-16-1P,  
 2-(2-Cyclohexylethyl)-4-(2,6-dimethyl-4-nitrophenyl)phenol 477274-17-2P,  
 4-(4-Amino-2,6-dimethylphenoxy)-2-(4-fluorophenoxy)phenol 477274-18-3P  
 477274-19-4P, Ethyl 4-(4-benzyloxy-3-isopropylbenzyl)-3,5-  
 dimethylmalonanilate  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preventive or recurrence-suppressive agents for liver cancer contg.  
 thyroid hormone receptor agonists)

TI Preparation of malonanilic acid derivatives as preventives or remedies for circulatory disease  
 IN Shiohara, Hiroaki; Nakamura, Tetsuya; Kikuchi, Norihiko; Ohnota, Hideki; Koizumi, Takashi; Kitazawa, Makio  
 PA Kissei Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 118 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085670	A1	20011115	WO 2001-JP3499	20010424
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI JP 2000-140743 A 20000512

OS MARPAT 135:371762

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT	<b>355129-15-6P</b>	<b>355129-23-6P</b>	364331-19-1P	364331-20-4P	
	364331-24-8P	364332-53-6P	364332-59-2P	364332-60-5P	373641-11-3P
	373641-12-4P	373641-13-5P	373641-14-6P	373641-15-7P	373641-17-9P
	373641-18-0P	373641-19-1P	373641-22-6P	373641-24-8P	373641-25-9P
	373641-27-1P	373641-29-3P	373641-31-7P	373641-34-0P	373641-38-4P
	<b>373641-40-8P</b>	373641-42-0P	373641-44-2P	373641-46-4P	
	373641-50-0P	373641-51-1P	373641-53-3P	373641-54-4P	373641-55-5P
	373641-56-6P	373641-57-7P	373641-58-8P	373641-59-9P	
	<b>373641-60-2P</b>	373641-61-3P	373641-62-4P	373641-63-5P	
	373641-64-6P	373641-65-7P	373641-66-8P	373641-67-9P	373641-68-0P
	373641-69-1P	373641-70-4P	373641-71-5P	373641-72-6P	373641-73-7P
	373641-74-8P	373641-75-9P	373641-76-0P	373641-77-1P	373641-78-2P
	373641-79-3P	373641-80-6P	373641-81-7P	373641-82-8P	373641-83-9P
	373641-84-0P	373641-85-1P	373641-86-2P	373641-87-3P	373641-88-4P
	373641-89-5P	373641-90-8P	373641-91-9P	373641-92-0P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of malonanilic acid derivs. lowering neutral fat level and non-HDL cholesterol level in blood as preventives or remedies for circulatory diseases)

IT	3886-19-9P	4049-39-2P	20404-02-8P	23860-35-7P, Cyclohexaneacetyl chloride	29417-96-7P	40500-05-8P	53906-85-7P	85064-61-5P
	89682-88-2P	92892-06-3P	103260-44-2P	112556-09-9P	117832-15-2P			
	130312-00-4P	156740-97-5P	224648-57-1P	355377-72-9P	373641-93-1P			
	373641-94-2P	373641-95-3P	373641-96-4P	373641-97-5P	373641-98-6P			
	373641-99-7P	373642-00-3P	373642-01-4P	373642-02-5P	373642-03-6P			
	373642-05-8P	373642-07-0P	373642-09-2P	373642-10-5P	373642-12-7P			
	373642-14-9P	373642-16-1P	373642-18-3P	373642-20-7P	373642-22-9P			
	373642-24-1P	373642-26-3P	373642-28-5P	373642-30-9P	373642-32-1P			
	373642-34-3P	373642-37-6P	373642-39-8P	373642-41-2P	373642-43-4P			
	373642-45-6P	373642-47-8P	373642-49-0P	373642-51-4P	373642-53-6P			
	373642-55-8P	373642-57-0P	373642-59-2P	373642-61-6P	373642-62-7P			
	373642-63-8P	373642-64-9P	373642-65-0P	373642-66-1P	373642-67-2P			
	373642-68-3P	373642-69-4P	373642-70-7P	373642-71-8P	373642-72-9P			
	373642-73-0P	373642-74-1P	373642-75-2P	373642-76-3P	373642-77-4P			

373642-78-5P	373642-79-6P	373642-80-9P	373642-81-0P	373642-82-1P
373642-83-2P	373642-84-3P	373642-85-4P	373642-86-5P	373642-87-6P
373642-88-7P	373642-89-8P	373642-90-1P	373642-91-2P	373642-92-3P
373642-93-4P	373642-94-5P	373642-95-6P	373642-96-7P	373642-97-8P
373642-98-9P	373642-99-0P	373643-00-6P	373643-01-7P	373643-02-8P
373643-03-9P	373643-04-0P	373643-05-1P	373643-06-2P	373643-07-3P
373643-08-4P	373643-09-5P	373643-10-8P	373643-11-9P	373643-12-0P
373643-13-1P	373643-14-2P	373643-15-3P	373643-16-4P	373643-17-5P
373643-18-6P	373643-19-7P	373643-20-0P	<b>373643-21-1P</b>	
373643-23-3P				

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of malonanilic acid derivs. lowering neutral fat level and non-HDL cholesterol level in blood as preventives or remedies for circulatory diseases)

L3 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2001:730688 CAPLUS  
 DN 135:288519  
 TI Preparation of N-phenylmalonamic acid derivatives with thyroid receptor ligand activity  
 IN Aspnes, Gary Erik; Chiang, Yuan-Ching Phoebe; Estep, Kimberly Gail  
 PA Pfizer Products Inc., USA  
 SO PCT Int. Appl., 176 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072692	A1	20011004	WO 2001-IB317	20010307
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP	1268404	A1	20030102	EP 2001-910082	20010307
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR	2001009625	A	20030422	BR 2001-9625	20010307
JP	2003528847	T2	20030930	JP 2001-570607	20010307
US	2001051657	A1	20011213	US 2001-819283	20010328
BG	107036	A	20030430	BG 2002-107036	20020826
NO	2002004639	A	20020927	NO 2002-4639	20020927
PRAI	US 2000-193618P	P	20000331		
	WO 2001-IB317	W	20010307		

OS MARPAT 135:288519

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 298695-13-3P, N-[4-[3-(4-Fluorobenzenesulfonyl)-4-hydroxyphenoxy]-3,5-dimethylphenyl]malonamic acid **355129-16-7P** 364331-20-4P  
**364331-21-5P** 364331-22-6P 364331-23-7P 364331-24-8P  
 364331-31-7P 364331-33-9P 364331-35-1P 364331-37-3P 364331-38-4P  
**364331-39-5P** 364331-40-8P 364331-41-9P 364331-42-0P  
 364331-43-1P 364331-44-2P 364331-45-3P 364331-47-5P 364331-48-6P  
 364331-49-7P 364331-50-0P **364331-55-5P** 364331-56-6P  
 364331-57-7P 364331-58-8P **364331-59-9P 364331-61-3P**  
**364331-63-5P 364331-65-7P** 364331-67-9P

364331-69-1P 364331-71-5P 364331-73-7P  
 364331-75-9P 364331-77-1P 364331-79-3P  
 364331-81-7P 364331-83-9P 364331-85-1P  
 364331-88-4P 364331-90-8P 364331-92-0P  
 364331-94-2P 364331-96-4P 364331-97-5P  
 364331-98-6P 364331-99-7P 364332-00-3P  
 364332-05-8P 364332-06-9P 364332-08-1P 364332-10-5P 364332-11-6P  
 364332-12-7P 364332-13-8P 364332-14-9P 364332-20-7P 364332-21-8P  
 364332-22-9P 364332-23-0P 364332-24-1P 364332-25-2P 364332-26-3P  
 364332-27-4P 364332-28-5P 364332-29-6P 364332-30-9P 364332-31-0P  
 364332-32-1P 364332-33-2P 364332-34-3P 364332-35-4P 364332-36-5P  
 364332-37-6P 364332-38-7P 364332-39-8P 364332-40-1P 364332-41-2P  
 364332-42-3P 364332-43-4P 364332-44-5P 364332-46-7P 364332-47-8P  
 364332-48-9P 364332-49-0P 364332-50-3P 364332-51-4P 364332-53-6P  
 364332-54-7P 364332-55-8P 364332-56-9P  
 364332-57-0P 364332-58-1P 364332-60-5P 364332-61-6P  
 364332-68-3P 364332-70-7P 364332-71-8P 364332-72-9P 364332-73-0P  
 364332-74-1P 364332-75-2P 364332-76-3P 364332-77-4P 364332-78-5P  
 364332-79-6P 364332-80-9P 364332-81-0P 364332-82-1P 364332-83-2P  
 364332-84-3P 364332-86-5P 364332-90-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-phenylmalonamates with thyroid receptor ligand activity)

IT 102914-99-8P, 2-(4-Fluorobenzenesulfonyl)benzene-1,4-diol 156740-86-2P  
 156740-87-3P 156740-88-4P 156740-96-4P 290349-18-7P,

5-(2,6-Dichloro-4-nitrophenoxy)-2-methoxybenzenesulfonyl chloride

290349-80-3P, 5-(2,6-Dichloro-4-nitrophenoxy)-2-methoxybenzaldehyde

290349-81-4P, 5-(2,6-Dichloro-4-nitrophenoxy)-2-methoxybenzoic acid

290351-96-1P 298695-35-9P, 4-(2,6-Dimethyl-4-nitrophenoxy)-2-(4-

fluorobenzenesulfonyl)phenol 298695-37-1P, 4-(4-Amino-2,6-

dimethylphenoxy)-2-(4-fluorobenzenesulfonyl)phenol 332933-91-2P

332933-93-4P 364331-18-0P 364331-19-1P 364331-25-9P 364331-26-0P

364331-27-1P 364331-28-2P 364331-51-1P 364331-52-2P 364331-53-3P

364331-54-4P 364332-01-4P 364332-02-5P 364332-03-6P

364332-04-7P 364332-07-0P 364332-09-2P 364332-15-0P 364332-16-1P

364332-18-3P 364332-19-4P 364332-52-5P 364332-59-2P 364332-62-7P

364332-63-8P 364332-64-9P 364332-65-0P 364332-67-2P 364332-69-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of N-phenylmalonamates with thyroid receptor ligand activity)

L3 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:617969 CAPLUS

DN 135:180607

TI Preparation of aniline-derived ligands for the thyroid receptor

IN Friends, Todd Jason; Ryono, Dennis E.; Zhang, Minsheng

PA Bristol-Myers Squibb Co., USA

SO PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060784	A1	20010823	WO 2001-US1204	20010112
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,				
	CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,				
	ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU,				
	LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,				
	SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,				
	ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1257526 A1 20021120 EP 2001-903064 20010112

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2001008134 A 20030930 BR 2001-8134 20010112

NO 2002003895 A 20021016 NO 2002-3895 20020816

PRAI US 2000-183223P P 20000217

WO 2001-US1204 W 20010112

OS MARPAT 135:180607

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT **355129-15-6P 355129-16-7P 355129-17-8P**  
**355129-18-9P 355129-19-0P 355129-20-3P**  
**355129-21-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of aniline-derived ligands for the thyroid receptor)

IT 156740-82-8P 169113-83-1P 258820-25-6P 355129-22-5P  
**355129-23-6P 355129-24-7P 355129-25-8P 355129-26-9P**  
**355129-27-0P 355129-28-1P 355129-29-2P 355129-30-5P**  
**355129-31-6P 355129-32-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of aniline-derived ligands for the thyroid receptor)

L3 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:219825 CAPLUS

DN 130:282476

TI Precursors for polybenzoxazoles and polybenzothiazoles

IN Sezi, Recai; Schmid, Gunter; Keitmann, Michael

PA Siemens Aktiengesellschaft, Germany

SO Eur. Pat. Appl., 14 pp.

CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 905169	A2	19990331	EP 1998-117333	19980912
	EP 905169	A3	20000112		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 11171994	A2	19990629	JP 1998-270388	19980924
	US 6153350	A	20001128	US 1998-161148	19980925
PRAI	DE 1997-19742132	A	19970924		
IT	222612-31-9P	222612-32-0P	222612-34-2P	222612-35-3P	222612-36-4P
	222612-37-5P	222612-38-6P	222612-39-7P	222612-40-0P	
	<b>222612-41-1P</b>	222612-42-2P	222612-43-3P	222612-45-5P	
	222612-47-7P	222725-09-9P	222725-10-2P		
	RL: IMF (Industrial manufacture); PREP (Preparation)				
	(precursors for polybenzoxazoles and polybenzothiazoles)				
IT	222612-31-9DP, cyclized	222612-32-0DP, cyclized	222612-34-2DP, cyclized	222612-35-3DP, cyclized	222612-36-4DP, cyclized
	222612-37-5DP, cyclized	222612-38-6DP, cyclized	222612-39-7DP, cyclized	222612-40-0DP, cyclized	<b>222612-41-1DP, cyclized</b>
	222612-42-2DP, cyclized	222612-43-3DP, cyclized	222612-45-5DP, cyclized	222612-47-7DP, cyclized	222725-09-9DP, cyclized
	222725-10-2DP, cyclized				
	RL: IMF (Industrial manufacture); PRP (Properties); PREP (Preparation)				



(prepn. of)

=> d bib, hitstr 5-

YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 2001:617969 CAPLUS  
DN 135:180607  
TI Preparation of aniline-derived ligands for the thyroid receptor  
IN Friends, Todd Jason; Ryono, Dennis E.; Zhang, Minsheng  
PA Bristol-Myers Squibb Co., USA  
SO PCT Int. Appl., 51 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060784	A1	20010823	WO 2001-US1204	20010112
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	EP 1257526	A1	20021120	EP 2001-903064	20010112
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	BR 2001008134	A	20030930	BR 2001-8134	20010112
	NO 2002003895	A	20021016	NO 2002-3895	20020816
PRAI	US 2000-183223P	P	20000217		
	WO 2001-US1204	W	20010112		

OS MARPAT 135:180607


IT **355129-15-6P 355129-16-7P 355129-17-8P**  
**355129-18-9P 355129-19-0P 355129-20-3P**  
**355129-21-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aniline-derived ligands for the thyroid receptor)

RN 355129-15-6 CAPLUS


CN Propanoic acid, 3-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 355129-16-7 CAPLUS


CN Propanoic acid, 3-[[3,5-dichloro-4-[4-hydroxy-3-(1-

methylethyl)phenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)




RN 355129-17-8 CAPLUS

CN Propanoic acid, 3-[[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-methylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)




RN 355129-18-9 CAPLUS

CN Butanoic acid, 4-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 355129-19-0 CAPLUS


CN Pentanoic acid, 5-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-5-oxo- (9CI) (CA INDEX NAME)



RN 355129-20-3 CAPLUS


CN 2-Butenoic acid, 4-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-4-oxo-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 355129-21-4 CAPLUS  
 CN 2-Butenoic acid, 4-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-4-oxo-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



IT 355129-23-6P 355129-26-9P 355129-30-5P  
 355129-31-6P 355129-32-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. of aniline-derived ligands for the thyroid receptor)  
 RN 355129-23-6 CAPLUS  
 CN Propanoic acid, 3-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 355129-26-9 CAPLUS  
 CN Propanoic acid, 3-[[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 355129-30-5 CAPLUS

CN Propanoic acid, 3-[[[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-methylphenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 355129-31-6 CAPLUS


CN Butanoic acid, 4-[[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-4-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 355129-32-7 CAPLUS

CN 2-Butenoic acid, 4-[[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-4-oxo-, methyl ester, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 1999:219825 CAPLUS  
 DN 130:282476  
 TI Precursors for polybenzoxazoles and polybenzothiazoles  
 IN Sezi, Recai; Schmid, Gunter; Keitmann, Michael  
 PA Siemens Aktiengesellschaft, Germany  
 SO Eur. Pat. Appl., 14 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 905169	A2	19990331	EP 1998-117333	19980912
	EP 905169	A3	20000112		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 11171994	A2	19990629	JP 1998-270388	19980924
	US 6153350	A	20001128	US 1998-161148	19980925
PRAI	DE 1997-19742132	A	19970924		
IT	<b>222612-41-1P</b>				
	RL: IMF (Industrial manufacture); PREP (Preparation) (precursors for polybenzoxazoles and polybenzothiazoles)				
RN	222612-41-1 CAPLUS				
CN	Poly[oxy(2,3,5,6-tetrafluoro-1,4-phenylene)oxy(2,3,6-trifluoro-5-hydroxy-1,4-phenylene)imino(1,6-dioxo-1,6-hexanediyl)imino(2,3,5-trifluoro-6-hydroxy-1,4-phenylene)] (9CI) (CA INDEX NAME)				

PAGE 1-A




PAGE 1-B

IT **222612-41-1DP**, cyclized  
 RL: IMF (Industrial manufacture); PRP (Properties); PREP (Preparation)  
 (prepn. of)  
 RN 222612-41-1 CAPLUS  
 CN Poly[oxy(2,3,5,6-tetrafluoro-1,4-phenylene)oxy(2,3,6-trifluoro-5-hydroxy-1,4-phenylene)imino(1,6-dioxo-1,6-hexanediyl)imino(2,3,5-trifluoro-6-

hydroxy-1,4-phenylene)] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

$n$